2.2.0.7 false Nature of Business and Basis of Presentation 0201 - Disclosure - Nature of Business and Basis of Presentation true false false false 1 USD false false USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 Pure Standard http://www.xbrl.org/2003/instance pure xbrli 0 $ 2 Nature of Business and Basis of Presentation [Abstract] 0 us-gaap_GeneralPoliciesAbstract us-gaap true na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 3 Nature of Business and Basis of Presentation 1 us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock us-gaap true na duration No definition available. false false false false false false false false false false false verboselabel false 1 false false false false 0 0   <div align="left" style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">   <div align="center" style="font-size: 10pt; margin-top: 0pt"><b></b> </div> <div align="left"> </div> <div align="center" style="font-size: 10pt"><b></b> <b></b> <b></b></div> <div align="justify" style="font-size: 10pt; margin-top: 10pt"><b>1. Nature of Business and Basis of Presentation</b> </div> <div align="justify" style="font-size: 10pt; margin-top: 10pt">Celgene Corporation and its subsidiaries (collectively “Celgene” or the “Company”) is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory diseases. </div> <div align="justify" style="font-size: 10pt; margin-top: 10pt">The Company’s primary commercial stage products include REVLIMID<sup style="font-size: 85%; vertical-align: text-top">®</sup>, VIDAZA<sup style="font-size: 85%; vertical-align: text-top">®</sup> and THALOMID<sup style="font-size: 85%; vertical-align: text-top">®</sup> (inclusive of Thalidomide Celgene<sup style="font-size: 85%; vertical-align: text-top">®</sup> and Thalidomide Pharmion<sup style="font-size: 85%; vertical-align: text-top">®</sup>). Other commercial stage products include ISTODAX<sup style="font-size: 85%; vertical-align: text-top">®</sup> and FOCALIN<sup style="font-size: 85%; vertical-align: text-top">®</sup>. ISTODAX<sup style="font-size: 85%; vertical-align: text-top">®</sup>, which was obtained in the acquisition of Gloucester Pharmaceuticals, Inc., or Gloucester, was approved in November 2009 by the U.S. Food and Drug Administration, or FDA, for the treatment of cutaneous T-cell lymphoma, or CTCL, in patients who have received at least one prior systemic therapy and was launched in the first quarter of the year ending December 31, 2010. FOCALIN<sup style="font-size: 85%; vertical-align: text-top">®</sup> is sold exclusively to Novartis Pharma AG, or Novartis. The Company’s other sources of revenues include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR<sup style="font-size: 85%; vertical-align: text-top">®</sup> and the entire RITALIN<sup style="font-size: 85%; vertical-align: text-top">®</sup> family of drugs. ALKERAN<sup style="font-size: 85%; vertical-align: text-top">®</sup> was licensed from GlaxoSmithKline, or GSK, and sold under the Celgene label through March 31, 2009, the conclusion date of the ALKERAN<sup style="font-size: 85%; vertical-align: text-top">®</sup> license with GSK. The Company continues to earn residual payments based upon GSK’s ALKERAN<sup style="font-size: 85%; vertical-align: text-top">®</sup> revenues through March 31, 2011. The Company also derives revenues from the sale of services through its Cellular Therapeutics subsidiary and miscellaneous licensing agreements. </div> <div align="justify" style="font-size: 10pt; margin-top: 10pt">The accompanying unaudited consolidated financial statements have been prepared from the books and records of the Company pursuant to U.S. generally accepted accounting principles for interim information and the rules and regulations of the Securities and Exchange Commission for interim reporting. Pursuant to such rules and regulations, certain information and footnote disclosures normally included in complete annual financial statements have been condensed or omitted. The consolidated financial statements include the accounts of Celgene Corporation and its subsidiaries. All intercompany transactions and balances have been eliminated. Investments in limited partnerships and interests in which the Company has an equity interest of 50% or less and does not otherwise have a controlling financial interest are accounted for by either the equity or cost method. The interim consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2009, or the 2009 Annual Report on Form 10-K. </div> <div align="justify" style="font-size: 10pt; margin-top: 10pt">The preparation of the consolidated financial statements requires management to make estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates. The Company is subject to certain risks and uncertainties related to product development, regulatory approval, market acceptance, scope of patent and proprietary rights, competition, technological change and product liability. </div> <div align="justify" style="font-size: 10pt; margin-top: 10pt">Interim results may not be indicative of the results that may be expected for the full year. In the opinion of management, these financial statements include all normal and recurring adjustments considered necessary for a fair presentation of these interim consolidated financial statements. Effective January 1, 2010, the Company changed the functional currency of Celgene International Sarl from the Euro to the U.S. Dollar. Significant changes in economic facts and circumstances supported this change in functional currency and the change was applied on a prospective basis. </div>   </div>  <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "> <div align="center" style="font-size: 10pt; margin-top: 0pt"> <b> </b> </div> </div>  <!-- Begin Block Tagged Note false false false us-types:textBlockItemType textblock Description containing the entire organization, consolidation and basis of presentation of financial statements disclosure. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Staff Position (FSP) -Number FAS140-4 and FIN46(R)-8 -Paragraph 8, C1, C7 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 2-6 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Statement of Position (SOP) -Number 94-6 -Paragraph 10 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Interpretation (FIN) -Number 46R -Paragraph 4, 14, 15 false 1 2 false UnKnown UnKnown UnKnown false true